
Lantheus Holdings, Inc. (NASDAQ:LNTH) dosed first patient in a Phase 2 trial evaluating NM-01, its proprietary technetium 99m SPECT imaging agent used to assess PD-L1 expression in cancer cells.
NM-01 is being investigated in the Phase 2 PELICAN single-arm trial in non-small cell lung cancer (NSCLC) patients.